Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Oct 30, 2008 | Senior VP, Drug Development | Open market or private sale of non-derivative or derivative security | Form 4 | 300 | $10.00 | 51,316 | |
| Oct 30, 2008 | Chief Operating Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 361 | $10.00 | 38,388 | |
| Oct 31, 2008 | Director | Open market or private sale of non-derivative or derivative security | Form 4 | 2,892 | $9.85 | 1,717,128 | |
| Oct 31, 2008 | Director | Open market or private sale of non-derivative or derivative security | Form 4 | 108 | $9.85 | 64,119 | |
| Oct 31, 2008 | Senior VP, Drug Development | Open market or private sale of non-derivative or derivative security | Form 4 | 2,200 | $10.00 | 49,116 | |
| Oct 31, 2008 | Chief Operating Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 1,939 | $10.00 | 36,449 | |
| Nov 03, 2008 | Director | Open market or private sale of non-derivative or derivative security | Form 4 | 2,892 | $10.24 | 1,714,236 | |
| Nov 03, 2008 | Director | Open market or private sale of non-derivative or derivative security | Form 4 | 108 | $10.24 | 64,011 | |
| Nov 03, 2008 | Director, President & CEO | Open market or private sale of non-derivative or derivative security | Form 4 | 5,000 | $10.27 | 18,033 | |
| Nov 03, 2008 | Director, President & CEO | Open market or private sale of non-derivative or derivative security | Form 4 | 5,000 | $10.29 | 5,200 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.